Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2021

View Archived Issues

First clinical data presented for BNT-211 in patients with CLDN6-positive solid tumors

Phase I dose-escalation study tests combination immunotherapy with belapectin and pembrolizumab

Galectin-3 mediates the crosstalk between the WNT and STAT3 signaling pathways in gastric cancer

Ono Pharmaceutical, Vanderbilt University present KCNT1/KCNK2 blockers

ReViral synthesizes new benzodiazepine derivatives

New anti-HBV compounds identified at Sunshine Lake Pharma

Suzhou Raymon Pharmaceuticals discovers PI3K-alpha inhibitors

ShanghaiTech University, Fudan University patent new PROTACs

New Angex Pharmaceutical anticancer compounds show preclinical potential

Full-data analysis from 12-month treatment phase of ALTISSIMO study in wet AMD

Nephraegis Therapeutics to develop NPH-022 for the prevention and treatment of AKI

New phase II trial evaluates CBP-201 for moderate to severe persistent asthma

Mitsubishi Tanabe discontinues development of MT-5745 for ulcerative colitis

Inovio reports preclinical data on next-generation pan-COVID-19 vaccine candidate INO-4802

Mabwell initiates first-in-human study of 9MW-1411

China's NMPA issues clinical trial approval for JS-103 for gout

Preclinical characterization of novel 3CL(pro) inhibitors against COVID-19

Clene Nanomedicine presents preliminary phase II data for CNM-Au8 in ALS

HU-6 enters phase II development as potential treatment of NASH

OCS-02 shows safety and efficacy in phase II study in patients with acute anterior uveitis

Dosing begins in phase II trial of onapristone and anastrozole in endometrial cancer

Xilio presents preclinical data on tumor-selective anti-CTLA-4 antibody XTX-101

AzurRx reports phase II interim data on MS-1819 for severe exocrine pancreatic insufficiency

Engineering blood cells can treat brain diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...